Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

By K. Strebhardt. Nature reviews. Drug discovery, 2010

667 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/01e4a10a926446bb77af86ef58b217ec5a74508e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. P. Muller
2. Karen H. Vousden

In Molecular Biology

1. P. Muller
2. Karen H. Vousden

In Oncology

1. P. Muller
2. Karen H. Vousden

Citations in the corpus

• Mutant p53 in Cancer: New Functions and Therapeutic Opportunities (2014, background): “Because PLK1 can be inhibited by a variety of compounds (Strebhardt, 2010), it will be interesting to follow up this lead.”